Cost Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England and Wales

Diana Weidlich, Laurent Servais, Imran Kausar, Ruth Howells, Matthias Bischof
doi: https://doi.org/10.1101/2023.02.09.23285715

Article Information

doi 
https://doi.org/10.1101/2023.02.09.23285715
History 
  • February 10, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Diana Weidlich1,*,
  2. Laurent Servais2,3,
  3. Imran Kausar4,
  4. Ruth Howells5 and
  5. Matthias Bischof6
  1. 1Health Economics, Clarivate, Frankfurt am Main, Germany
  2. 2MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK
  3. 3Neuromuscular Center of Liège, Department of Paediatrics, Hospital and University of Liège, Liège, Belgium
  4. 4Novartis Gene Therapies, London, UK
  5. 5Health Technology Assessment, Clarivate, Manchester, UK
  6. 6Novartis Gene Therapies GmbH, Rotkreuz, Switzerland
  1. ↵*Corresponding Author:
    Diana Weidlich, MSc, Clarivate, Mayfarthstrasse 11, Frankfurt am Main 60314, Germany, E-mail: Diana.Weidlich{at}Clarivate.com
Back to top
Posted February 10, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Cost Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England and Wales
Diana Weidlich, Laurent Servais, Imran Kausar, Ruth Howells, Matthias Bischof
medRxiv 2023.02.09.23285715; doi: https://doi.org/10.1101/2023.02.09.23285715
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area